Summary of Significant Accounting Policies - Narrative (Details)				1 Months Ended						12 Months Ended		55 Months Ended	67 Months Ended
	Apr. 28, 2020 USD ($)	Apr. 23, 2020 USD ($)	Jan. 07, 2020 USD ($)	Jan. 31, 2020 shares	Dec. 31, 2019 USD ($)	Oct. 31, 2018 shares	Oct. 31, 2017 USD ($)	May 31, 2017 USD ($)	May 31, 2016 USD ($)	Dec. 31, 2021 USD ($) segment shares	Dec. 31, 2020 USD ($) shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2021 USD ($) shares	Oct. 31, 2021 USD ($)	Sep. 30, 2018	Nov. 01, 2017 USD ($)
Accumulated deficit										$ 165,718,953	$ 130,647,485	$ 165,718,953	$ 165,718,953
Net loss										35,400,807	26,381,389
Cash, cash equivalents and short term investments										$ 96,400,000		96,400,000	96,400,000
Proceeds from PPP loan											702,000
Repayment of PPP loan											$ 702,000
Number of reportable segments | segment										1
Percent of revenue generated in the United States										100.00%	100.00%
Derivative warrant liability										$ 11,020	$ 33,779	11,020	11,020
Cash balance insured										250,000	$ 250,000	250,000	250,000
Cash balance uninsured										7,500,658		7,500,658	7,500,658
Other assets										12,193,540		12,193,540	12,193,540
Common stock issued in exchange for warrants (in shares) | shares											319,756
Fair value of the contingent consideration										430,000	$ 1,199,000
Goodwill gross											1,452,338
Goodwill impairment loss										1,452,338	0
Balance of finite-lived intangible assets										3,500,000	5,866,000	3,500,000	3,500,000
Intangible assets fair value										3,500,000		3,500,000	3,500,000
Impairment loss										2,366,000
Unrecognized tax benefit										$ 0	$ 0	$ 0	$ 0
Percentage of non-controlling interest acquired										15.00%	15.00%	15.00%	15.00%
Revenue										$ 2,112,806	$ 2,947,969
Remaining grant amount receivable										1,300,000		$ 1,300,000	$ 1,300,000
Allowable expenses incurred under NIH grant										100,000
Maximum
Aggregate public offering price		$ 150,000,000
Amount awarded from NIH grant			$ 224,713
In-process R&D
Balance of finite-lived intangible assets										3,500,000	5,866,000	3,500,000	3,500,000
Intangible assets fair value										3,500,000		3,500,000	$ 3,500,000
Impairment loss										$ 2,366,000	$ 0.0
Grant revenue
Revenue												$ 13,700,000
San Antonio, TX
Number of square feet of space leased														20,144
Lab equipment
Useful life										P5Y
Computers
Useful life										P3Y
Furniture and fixtures
Useful life										P8Y
Leasehold Improvements
Useful life										P5Y
Common stock warrants
Number of warrants reclassified to liability | shares				479,595
Warrants exchanged | shares										0	470,238
Warrants outstanding | shares										9,357		9,357	9,357
At The Market Offerings | Maximum
Percentage of commission fees to sales agent		3.00%
Heat I
Ownership interest in subsidiary						100.00%
Pelican Therapeutics, Inc.
Ownership interest in subsidiary						85.00%				85.00%	85.00%	85.00%	85.00%		80.00%
CPRIT
Remaining grant amount receivable																$ 200,000
CPRIT | Grant revenue
Remaining grant amount receivable										$ 1,500,000		$ 1,500,000	$ 1,500,000
Heat I, Inc. and Pelican
Proceeds from PPP loan		$ 700,000
Repayment of PPP loan	$ 700,000
Shares issued in acquisition | shares						35,000
Pelican Therapeutics, Inc.
Amount awarded from CPRIT grant									$ 15,200,000
Pelican Therapeutics, Inc. | Grant revenue
Revenue													13,700,000
Remaining grant amount receivable										$ 1,500,000		$ 1,500,000	$ 1,500,000
Pelican Therapeutics, Inc. | First tranche | Grant revenue
Revenue								$ 1,800,000
Pelican Therapeutics, Inc. | Second tranche | Grant revenue
Revenue							$ 6,500,000
Pelican Therapeutics, Inc. | Third tranche | Grant revenue
Revenue					$ 5,400,000